IL-12 gene therapy for cancer: In synergy with other immunotherapies

Ignacio Melero, Guillermo Mazzolini, Iñigo Narvaiza, Cheng Qian, Lieping Chen, Jesús Prieto

Research output: Contribution to journalArticle

Abstract

In preclinical models of cancer, gene therapy with interleukin 12 (IL-12) has reached unprecedented levels of success when combined with immunotherapy approaches such as gene transfer of other cytokines and/or chemokines, costimulatory molecules or adoptive cell therapy. These combinations have been found to produce synergistic rather than additive effects. Meanwhile, IL-12 gene therapy is beginning clinical testing as a single agent, but combination strategies are at hand.

Original languageEnglish (US)
Pages (from-to)113-115
Number of pages3
JournalTrends in Immunology
Volume22
Issue number3
DOIs
StatePublished - 2001
Externally publishedYes

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'IL-12 gene therapy for cancer: In synergy with other immunotherapies'. Together they form a unique fingerprint.

  • Cite this

    Melero, I., Mazzolini, G., Narvaiza, I., Qian, C., Chen, L., & Prieto, J. (2001). IL-12 gene therapy for cancer: In synergy with other immunotherapies. Trends in Immunology, 22(3), 113-115. https://doi.org/10.1016/S1471-4906(00)01824-X